MAP
KYMR icon

Moody Aldrich Partners’s Kymera Therapeutics KYMR Stock Holding History

Moody Aldrich Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44M Sell
30,006
-8,189
-21% -$704K 0.62% 79
2026
Q1 		$3.18M Sell
38,195
-340
-0.9% -$26.9K 0.57% 84
2025
Q4 		$3M Buy
38,535
+9,625
+33% +$650K 0.56% 80
2025
Q3 		$1.64M Sell
28,910
-5,887
-17% -$266K 0.31% 107
2025
Q2 		$1.52M Buy
+34,797
New +$1.2M 0.29% 102

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Moody Aldrich Partners's KYMR Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Kymera Therapeutics (KYMR) stake by 21% in Q2 2026, selling an estimated $704K and leaving 30,006 shares worth $3.44M. The position accounts for 0.62% of the portfolio, ranked #79.

Moody Aldrich Partners first reported a position in KYMR in Q2 2025 and has held it in 5 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Moody Aldrich Partners held 30,006 shares of Kymera Therapeutics worth $3.44M as of Q2 2026.
  • Moody Aldrich Partners sold 8,189 Kymera Therapeutics shares in Q2 2026, an estimated $704K.
  • Kymera Therapeutics made up 0.62% of Moody Aldrich Partners's portfolio in Q2 2026, its #79 holding.
  • Moody Aldrich Partners first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.